Pacific Biosciences of California (PACB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PACB Stock Forecast

Pacific Biosciences of California stock forecast is as follows: an average price target of $3.00 (represents a 69.49% upside from PACB’s last price of $1.77) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

PACB Price Target

The average price target for Pacific Biosciences of California (PACB) is $3.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $2.00. This represents a potential 69.49% upside from PACB's last price of $1.77.

PACB Analyst Ratings

Buy

According to 9 Wall Street analysts, Pacific Biosciences of California's rating consensus is 'Buy'. The analyst rating breakdown for PACB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (55.56%), 3 'Hold' (33.33%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

Pacific Biosciences of California Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 03, 2024	Tycho Peterson	Jefferies	-	-	123.46%	125.99%
May 13, 2024	Tejas Savant	Morgan Stanley	-	-	102.53%	125.99%
May 13, 2024	David Westenberg	Piper Sandler	-	-	12.99%	12.99%
May 10, 2024	Luke Sergott	Barclays	-	-	16.28%	12.99%
Apr 18, 2024	Matthew Sykes	Goldman Sachs	-	-	78.57%	41.24%
Apr 16, 2024	Kyle Mikson	Canaccord Genuity	-	-	150.00%	97.74%
Nov 16, 2022		Canaccord Genuity	-	-	29.57%	690.96%
Aug 17, 2022	David Westenberg	Piper Sandler	-	-	-1.45%	323.73%
May 15, 2022	David Westenberg	Piper Sandler	-	-	2.74%	238.98%
Jan 12, 2022	David Westenberg	Piper Sandler	-	-	38.41%	1029.94%

Row per page

Go to

The latest Pacific Biosciences of California stock forecast, released on Jun 03, 2024 by Tycho Peterson from Jefferies, set a price target of $4.00, which represents a 123.46% increase from the stock price at the time of the forecast ($1.79), and a 125.99% increase from PACB last price ($1.77).

Pacific Biosciences of California Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	6
Avg Price Target	-	-	$3.00
Last Closing Price	$1.77	$1.77	$1.77
Upside/Downside	-100.00%	-100.00%	69.49%

In the current month, the average price target of Pacific Biosciences of California stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pacific Biosciences of California's last price of $1.77. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 28, 2024	Morgan Stanley	Underperform	Underperform	Hold
Aug 28, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Aug 12, 2024	Morgan Stanley	Buy	Buy	Hold
Aug 12, 2024	Jefferies	Underperform	Underperform	Hold
Jun 03, 2024	Jefferies		Buy	Initialise
May 13, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
May 13, 2024	Piper Sandler	Neutral	Neutral	Hold
May 10, 2024	Barclays	Equal-Weight	Equal-Weight	Hold
Apr 18, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Apr 18, 2024	Bernstein	Outperform	Outperform	Hold

Row per page

Go to

Pacific Biosciences of California's last stock rating was published by Morgan Stanley on Aug 28, 2024. The company gave PACB a "Underperform" rating, the same as its previous rate.

Pacific Biosciences of California Financial Forecast

Pacific Biosciences of California Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$55.69M	$47.57M	$38.90M	$27.35M	$32.31M	$35.47M	$33.17M	$36.02M	$34.89M	$30.61M	$29.00M	$27.14M	$19.08M	$17.08M	$15.60M	$27.93M	$21.91M
Avg Forecast	$66.68M	$62.48M	$56.37M	$57.90M	$54.20M	$49.41M	$45.67M	$42.62M	$40.65M	$41.95M	$40.88M	$43.44M	$57.47M	$48.76M	$40.18M	$34.38M	$26.20M	$35.40M	$35.16M	$32.91M	$36.12M	$33.60M	$29.99M	$25.58M	$24.79M	$20.33M	$13.72M	$20.07M	$25.49M	$27.04M
High Forecast	$75.80M	$71.03M	$64.08M	$65.83M	$61.62M	$56.17M	$51.92M	$46.74M	$42.08M	$42.23M	$40.88M	$49.39M	$59.28M	$50.80M	$45.68M	$39.08M	$29.79M	$35.40M	$35.16M	$32.91M	$36.12M	$33.60M	$29.99M	$25.58M	$24.79M	$20.33M	$13.72M	$20.07M	$25.49M	$27.04M
Low Forecast	$62.89M	$58.93M	$53.17M	$54.61M	$51.12M	$46.60M	$43.08M	$39.67M	$39.96M	$41.67M	$40.88M	$40.97M	$54.82M	$47.38M	$37.90M	$32.43M	$24.71M	$35.40M	$35.16M	$32.91M	$36.12M	$33.60M	$29.99M	$25.58M	$24.79M	$20.33M	$13.72M	$20.07M	$25.49M	$27.04M
# Analysts	3	3	4	5	4	5	2	7	9	4	4	4	5	9	6	4	3	7	4	3	4	7	4	4	4	5	9	6	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14%	1.18%	1.13%	1.04%	0.91%	1.01%	1.01%	1.00%	1.04%	1.02%	1.13%	1.09%	0.94%	1.24%	0.78%	1.10%	0.81%

Pacific Biosciences of California's average Quarter revenue forecast for Dec 23 based on 5 analysts is $57.47M, with a low forecast of $54.82M, and a high forecast of $59.28M. PACB's average Quarter revenue forecast represents a 3.20% increase compared to the company's last Quarter revenue of $55.69M (Sep 23).

Pacific Biosciences of California EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	9	4	4	4	5	9	6	4	3	7	4	3	4	7	4	4	4	5	9	6	4	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-64.54M	$-62.27M	$-72.13M	$-76.14M	$-69.03M	$-73.15M	$-78.86M	$-60.97M	$-71.90M	$-35.02M	$-83.25M	$74.41M	$-21.39M	$-20.81M	$3.90M	$3.10M	$-25.90M
Avg Forecast	$-43.92M	$-41.15M	$-37.13M	$-38.14M	$-35.70M	$-32.54M	$-30.08M	$-28.07M	$-26.78M	$-27.63M	$-26.93M	$-82.78M	$-37.86M	$-32.12M	$-26.47M	$-75.25M	$-62.28M	$-35.40M	$-35.16M	$-59.49M	$-36.12M	$-33.60M	$-29.99M	$-85.06M	$-24.79M	$-20.33M	$-13.72M	$7.23M	$-25.49M	$-27.04M
High Forecast	$-41.42M	$-38.82M	$-35.02M	$-35.97M	$-33.67M	$-30.70M	$-28.38M	$-26.13M	$-26.32M	$-27.45M	$-26.93M	$-66.22M	$-36.11M	$-31.21M	$-24.96M	$-60.20M	$-49.82M	$-35.40M	$-35.16M	$-47.59M	$-36.12M	$-33.60M	$-29.99M	$-68.05M	$-24.79M	$-20.33M	$-13.72M	$8.68M	$-25.49M	$-27.04M
Low Forecast	$-49.93M	$-46.79M	$-42.21M	$-43.36M	$-40.59M	$-37.00M	$-34.20M	$-30.79M	$-27.72M	$-27.82M	$-26.93M	$-99.33M	$-39.05M	$-33.46M	$-30.09M	$-90.30M	$-74.73M	$-35.40M	$-35.16M	$-71.38M	$-36.12M	$-33.60M	$-29.99M	$-102.07M	$-24.79M	$-20.33M	$-13.72M	$5.78M	$-25.49M	$-27.04M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.01%	2.35%	0.96%	1.22%	1.95%	2.08%	1.33%	1.69%	2.14%	1.17%	0.98%	-3.00%	1.05%	1.52%	0.54%	-0.12%	0.96%

4 analysts predict PACB's average Quarter EBITDA for Mar 21 to be $-85.06M, with a high of $-68.05M and a low of $-102.07M. This is -214.31% lower than Pacific Biosciences of California's previous annual EBITDA (Dec 20) of $74.41M.

Pacific Biosciences of California Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	9	4	4	4	5	9	6	4	3	7	4	3	4	7	4	4	4	5	9	6	4	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-66.87M	$-69.83M	$-81.15M	$-79.84M	$-83.60M	$-69.38M	$-84.41M	$-69.33M	$16.54M	$-41.00M	$-87.44M	$74.94M	$-23.71M	$-23.09M	$1.26M	$-91.00K	$-29.12M
Avg Forecast	$-45.83M	$-37.36M	$-47.66M	$-48.99M	$-48.53M	$-46.19M	$-49.69M	$-50.49M	$-56.06M	$-60.24M	$-63.59M	$-91.46M	$-78.31M	$-78.95M	$-87.32M	$-83.14M	$-70.81M	$-90.34M	$-92.16M	$-65.72M	$-77.17M	$-60.47M	$-56.11M	$-89.34M	$115.69M	$-36.50M	$-49.03M	$2.34M	$-44.49M	$-40.86M
High Forecast	$-42.44M	$-34.60M	$-44.14M	$-45.38M	$-44.94M	$-42.78M	$-46.02M	$-41.58M	$-44.85M	$-55.79M	$-58.89M	$-73.17M	$-65.68M	$-64.15M	$-80.88M	$-66.51M	$-56.65M	$-90.34M	$-92.16M	$-52.58M	$-77.17M	$-60.47M	$-56.11M	$-71.47M	$115.69M	$-36.50M	$-49.03M	$2.81M	$-44.49M	$-40.86M
Low Forecast	$-53.98M	$-44.01M	$-56.14M	$-57.71M	$-57.16M	$-54.41M	$-58.53M	$-68.31M	$-78.49M	$-70.96M	$-74.90M	$-109.75M	$-83.36M	$-162.84M	$-102.86M	$-99.77M	$-84.98M	$-90.34M	$-92.16M	$-78.87M	$-77.17M	$-60.47M	$-56.11M	$-107.20M	$115.69M	$-36.50M	$-49.03M	$1.87M	$-44.49M	$-40.86M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.85%	0.80%	0.98%	1.13%	0.93%	0.75%	1.28%	0.90%	-0.27%	0.73%	0.98%	0.65%	0.65%	0.47%	0.54%	0.00%	0.71%

Pacific Biosciences of California's average Quarter net income forecast for Dec 21 is $-77.17M, with a range of $-77.17M to $-77.17M. PACB's average Quarter net income forecast represents a -566.54% decrease compared to the company's last Quarter net income of $16.54M (Sep 21).

Pacific Biosciences of California SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	9	4	4	4	5	9	6	4	3	7	4	3	4	7	4	4	4	5	9	6	4	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$43.43M	$40.57M	$39.82M	$45.00M	$36.80M	$39.25M	$39.80M	$37.32M	$31.61M	$29.06M	$26.14M	$17.95M	$14.77M	$15.13M	$24.95M	$16.58M	$20.07M
Avg Forecast	$64.07M	$60.04M	$54.17M	$55.64M	$52.09M	$47.48M	$43.89M	$40.95M	$39.07M	$40.31M	$39.29M	$41.75M	$55.23M	$46.86M	$38.61M	$33.04M	$25.18M	$33.80M	$33.57M	$32.10M	$34.48M	$32.08M	$28.63M	$24.42M	$23.66M	$19.41M	$13.10M	$19.16M	$24.33M	$25.81M
High Forecast	$72.85M	$68.26M	$61.58M	$63.26M	$59.22M	$53.98M	$49.90M	$44.91M	$40.44M	$40.58M	$39.29M	$47.46M	$56.97M	$48.82M	$43.90M	$37.56M	$28.63M	$33.80M	$33.57M	$38.52M	$34.48M	$32.08M	$28.63M	$24.42M	$23.66M	$19.41M	$13.10M	$19.16M	$24.33M	$25.81M
Low Forecast	$60.44M	$56.63M	$51.09M	$52.48M	$49.13M	$44.78M	$41.40M	$38.12M	$38.40M	$40.04M	$39.29M	$39.37M	$52.68M	$45.54M	$36.42M	$31.16M	$23.75M	$33.80M	$33.57M	$25.68M	$34.48M	$32.08M	$28.63M	$24.42M	$23.66M	$19.41M	$13.10M	$19.16M	$24.33M	$25.81M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.93%	1.05%	1.21%	1.79%	1.09%	1.17%	1.24%	1.08%	0.99%	1.01%	1.07%	0.76%	0.76%	1.15%	1.30%	0.68%	0.78%

Pacific Biosciences of California's average Quarter SG&A projection for Dec 23 is $55.23M, based on 5 Wall Street analysts, with a range of $52.68M to $56.97M. The forecast indicates a 27.17% rise compared to PACB last annual SG&A of $43.43M (Sep 23).

Pacific Biosciences of California EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	9	4	4	4	5	9	6	4	3	7	4	3	4	7	4	4	4	5	9	6	4	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.26	$-0.28	$-0.34	$-0.35	$-0.37	$-0.31	$-0.38	$-0.31	$0.08	$-0.21	$-0.45	$0.40	$-0.14	$-0.15	$0.01	$-0.00	$-0.19
Avg Forecast	$-0.17	$-0.14	$-0.17	$-0.18	$-0.18	$-0.17	$-0.18	$-0.19	$-0.21	$-0.22	$-0.23	$-0.28	$-0.29	$-0.29	$-0.32	$-0.33	$-0.36	$-0.33	$-0.34	$-0.32	$-0.28	$-0.22	$-0.21	$-0.46	$0.42	$-0.13	$-0.18	$-0.16	$-0.16	$-0.15
High Forecast	$-0.16	$-0.13	$-0.16	$-0.17	$-0.16	$-0.16	$-0.17	$-0.15	$-0.16	$-0.20	$-0.22	$-0.26	$-0.24	$-0.24	$-0.30	$-0.31	$-0.33	$-0.33	$-0.34	$-0.32	$-0.28	$-0.22	$-0.21	$-0.46	$0.42	$-0.13	$-0.18	$-0.16	$-0.16	$-0.15
Low Forecast	$-0.20	$-0.16	$-0.21	$-0.21	$-0.21	$-0.20	$-0.21	$-0.25	$-0.29	$-0.26	$-0.27	$-0.32	$-0.31	$-0.60	$-0.38	$-0.39	$-0.42	$-0.33	$-0.34	$-0.32	$-0.28	$-0.22	$-0.21	$-0.46	$0.42	$-0.13	$-0.18	$-0.16	$-0.16	$-0.15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	0.88%	1.02%	0.97%	1.12%	0.92%	1.19%	1.09%	-0.36%	1.02%	0.98%	0.94%	1.04%	0.83%	-0.06%	0.00%	1.27%

According to 4 Wall Street analysts, Pacific Biosciences of California's projected average Quarter EPS for Dec 21 is $-0.28, with a low estimate of $-0.28 and a high estimate of $-0.28. This represents a -454.16% decrease compared to PACB previous annual EPS of $0.08 (Sep 21).

Pacific Biosciences of California Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
NTLA	Intellia Therapeutics	-	-	739.86%	Buy
EDIT	Editas Medicine	-	-	442.19%	Buy
CRSP	CRISPR Therapeutics	-	-	119.18%	Buy
PACB	Pacific Biosciences of California	-	-	69.49%	Buy
TWST	Twist Bioscience	-	-	1.78%	Buy

PACB Forecast FAQ

Is Pacific Biosciences of California a good buy?

Yes, according to 9 Wall Street analysts, Pacific Biosciences of California (PACB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 55.56% of PACB's total ratings.

What is PACB's price target?

Pacific Biosciences of California (PACB) average price target is $3 with a range of $2 to $4, implying a 69.49% from its last price of $1.77. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pacific Biosciences of California stock go up soon?

According to Wall Street analysts' prediction for PACB stock, the company can go up by 69.49% (from the last price of $1.77 to the average price target of $3), up by 125.99% based on the highest stock price target, and up by 12.99% based on the lowest stock price target.

Can Pacific Biosciences of California stock reach $3?

PACB's highest twelve months analyst stock price target of $4 supports the claim that Pacific Biosciences of California can reach $3 in the near future.

What are Pacific Biosciences of California's analysts' financial forecasts?

Pacific Biosciences of California's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $191.89M (high $216.45M, low $180.47M), average EBITDA is $-126M (high $-119M, low $-143M), average net income is $-195M (high $-175M, low $-238M), average SG&A $184.41M (high $208.01M, low $173.43M), and average EPS is $-0.714 (high $-0.642, low $-0.874). PACB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $243.42M (high $276.75M, low $229.6M), average EBITDA is $-160M (high $-151M, low $-182M), average net income is $-180M (high $-167M, low $-212M), average SG&A $233.93M (high $265.95M, low $220.64M), and average EPS is $-0.659 (high $-0.61, low $-0.776).

Did the PACB's actual financial results beat the analysts' financial forecasts?

Based on Pacific Biosciences of California's last annual report (Dec 2022), the company's revenue was $128.3M, which missed the average analysts forecast of $129.68M by -1.06%. Apple's EBITDA was $-297M, beating the average prediction of $-192M by 54.52%. The company's net income was $-297M, missing the average estimation of $-319M by -6.93%. Apple's SG&A was $160.85M, beating the average forecast of $124.65M by 29.05%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-1.35 by -2.25%. In terms of the last quarterly report (Sep 2023), Pacific Biosciences of California's revenue was $55.69M, beating the average analysts' forecast of $48.76M by 14.21%. The company's EBITDA was $-64.538M, beating the average prediction of $-32.12M by 100.93%. Pacific Biosciences of California's net income was $-66.869M, missing the average estimation of $-78.954M by -15.31%. The company's SG&A was $43.43M, missing the average forecast of $46.86M by -7.32%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.289 by -10.13%